Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes
The Pro12Ala polymorphism of peroxisome proliferator-activated receptor (PPAR)γ has been consistently associated with Type 2 diabetes. The rare Ala12 variant is estimated to reduce the risk of developing Type 2 diabetes by 20 percent. This variant is in linkage disequilibrium with another common variant, T1431. Both have opposing associations with body weight. We therefore examined the association of specific haplotypes marked by these two variants with susceptibility to Type 2 diabetes.
We determined the PPARG genotype of a large Scottish cohort of Type 2 diabetic patients (n=1997) and compared allele frequencies with a cohort of local children (n=2444) and a middle-aged, population-based cohort from Scotland (n=1061).
Frequency of the Ala12 allele was slightly lower in the Type 2 diabetic cohort than in the children [odds ratio (OR)=0.91, p=0.1]. In contrast, the Ala12 variant was under-represented in the Type 2 diabetic population when compared with similarly aged non-diabetic adults (OR=0.74, p=0.0006). When the Ala12 variant was on a haplotype not bearing the 1431T variant, it conferred greater protection (OR=0.66, p=0.003). However, when it was present in haplotypes containing the 1431T variant (70% of Ala12 carriers), this protection was absent (OR=0.99, p=0.94).
We replicated the finding that the Ala12 variant of PPARγ affords protection from Type 2 diabetes, and suggest that this protection is modulated by additional common variation at the PPARG locus.
- Deeb SS, Fajas L, Nemoto M, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287 CrossRef
- Luan J, Browne PO, Harding AH et al. (2001) Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50:686–689
- Doney A, Fischer B, Frew D et al. (2002) Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3:21 CrossRef
- Morris AD, Boyle DI, MacAlpine R et al. (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315:524–528
- McGuigan FE, Armbrecht G, Smith R, Felsenberg D, Reid DM, Ralston SH (2001) Prediction of osteoporotic fractures by bone densitometry and COLIA1 genotyping: a prospective, population-based study in men and women. Osteoporos Int 12:91–96 CrossRef
- Ek J, Andersen G, Urhammer SA et al. (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44:1170–1176 CrossRef
- Ardlie KG, Lunetta KL, Seielstad M (2002) Testing for population subdivision and association in four case-control studies. Am J Hum Genet 71:304–311 CrossRef
- Ridker PM, Cook NR, Cheng S et al. (2003) Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 23:859–863 CrossRef
- Ostgren CJ, Lindblad U, Melander O, Melander A, Groop L, Rastam L (2003) Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project. J Hypertens 21:1657–1662 CrossRef
- Rodriguez-Esparragon FJ, Rodriguez-Perez JC, Macias-Reyes A, Alamo-Santana F (2003) Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/bgene polymorphisms are associated with essential hypertension. J Hypertens 21:1649–1655 CrossRef
- Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes
Volume 47, Issue 3 , pp 555-558
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Type 2 diabetes
- peroxisome proliferator
- Industry Sectors
- Author Affiliations
- 3. Department of Clinical Pharmacology, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom
- 1. Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee, DD1 9SY, Scotland, United Kingdom
- 4. Department of Psychology, University of Dundee, Dundee, Scotland, United Kingdom
- 5. University of Aberdeen Medical School, Institute of Medical Sciences, Aberdeen, Scotland, United Kingdom
- 2. Department of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom